Global Thymus (T)-Cell Therapy Market, By Modality (Research, Commercialized), Therapy (CAR T-cell Based, T Cell Receptor (TCR) Based, Tumor Infiltrating Lymphocytes (TIL) Based), Indication (Hematologic Malignancies, Solid Tumors, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029
Market Analysis and Size
T cell therapy is a type of immunotherapy that is used to treat cancer by altering T cells, which are part of the immune system. T cells were taken from a person's blood sample and then genetically engineered to develop specific structures on their surface known as chimeric antigen receptors (CARs). T-cell therapy is currently approved by the FDA as standard of care for certain types of aggressive, relapsed, or refractory non-Hodgkin lymphoma, such as diffuse large B cell lymphoma, primary mediastinal B-cell lymphoma, high grade B-cell lymphoma, transformed follicular lymphoma, and mantle cell lymphoma. T-cell treatment is also approved for patients under the age of 25 who have relapsed or refractory acute lymphoblastic leukemia.
Data Bridge Market Research analyses that the thymus (T)-cell therapy market was valued at USD 5.45 billion in 2021 and is expected to reach USD 21.28 billion by 2029, registering a CAGR of 18.55% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014-2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Modality (Research, Commercialized), Therapy (CAR T-cell Based, T Cell Receptor (TCR) Based, Tumor Infiltrating Lymphocytes (TIL) Based), Indication (Hematologic Malignancies, Solid Tumors, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Sanofi (France), F. Hoffmann-La Roche Ltd. (Switzerland), Bristol-Myers Squibb Company (US), Merck KGaA (Germany), Aurora Health Care (US), bluebird bio, Inc. (US), Amgen Inc. (US), Gilead Sciences, Inc. (US), Aurora Biopharma. (US), Fate Therapeutics (US), Mustang Bio (US), Sorrento Therapeutics Inc. (US), TCR² Therapeutics (US), Bayer AG (Germany), Bellicum Pharmaceuticals Inc. (US), AstraZeneca (UK), Johnson & Johnson Private Limited (US)
|
|
Market Opportunities
|
|
Market Definition
T-cell therapy is an immunotherapy technique known as adoptive cell transfer (ACT), in which the patient's own immune cells are used to treat cancer. It entails using apheresis to extract T-cells and reengineering them in the lab. These re-engineered cells are then reproduced and injected into the body, where they recognize and kill cancer cells that have specific antigens on their surfaces. A growing number of T-cell treatments are now being tested in clinical trials. One of these studies is the creation of an off-the-shelf technology for collecting immune cells from healthy donors and making them immediately available for use.
Thymus (T)-Cell Therapy Market Dynamics
Drivers
- High prevalence rate of cancer
The rise in prevalence rate of cancer will act as a major driver that will result in the expansion of the growth rate of the market. Increasing tobacco use, unhealthy eating habits and sedentary lifestyles of people, all of which contribute to an increased risk of cancer. As a result, the market is expected to rise in response to the rising global prevalence of cancer. According to the American Cancer Society, 28.4 million new cancer cases are expected to be diagnosed in 2040. This, together with an increase in the number of people diagnosed with bone marrow and blood-forming tissue illnesses, is one of the key factors driving demand for T-cell therapy.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of thymus (T)-cell therapy market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.
Furthermore, rising initiatives by public and private organizations to spread awareness and surging geriatric population will expand the thymus (T)-cell therapy market. Additionally, favourable reimbursement policies and growing government favourable initiatives will result in the expansion of thymus (T)-cell therapy market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the thymus (T)-cell therapy market growth. The widespread spread of coronavirus illness (COVID-19) has prompted researchers all around the world to consider T-cell therapy as a treatment option for high-risk patients. T-cell therapies were also recently approved by the US Food and Drug Administration (USFDA) to treat children with acute lymphoblastic leukemia (ALL) and adults with advanced lymphomas. As a result, producers are expected to benefit from attractive prospects and the market will increase.
- New product launches
Over the projected period, new product launches by industry players in the thymus (T)-cell therapy market due to high demand from the general public are estimated to promote new market opportunities. For instance, the US Food and Drug Administration authorized Tecartus (brexucabtagene autoleucel), a cell-based gene therapy, in July 2020 for the treatment of adult patients with mantle cell lymphoma (MCL) who have not responded to or relapsed after prior treatments. The FDA has approved Tecartus, a chimeric antigen receptor (CAR) T cell therapy, as the first cell-based gene therapy for MCL.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the thymus (T)-cell therapy market growth during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with the treatment will obstruct the growth rate of thymus (T)-cell therapy market during the forecast period of 2022-2029. The lack of healthcare infrastructure in developing economies and the dearth of skilled professionals will challenge the thymus (T)-cell therapy market. Additionally, side effects associated with therapy such as nausea, hair loss, vomiting and others and lack of awareness about the treatment will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This thymus (T)-cell therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the thymus (T)-cell therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Thymus (T)-cell therapy market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Thymus (T)-Cell Therapy Market
The private healthcare sector is one of the areas where the pandemic had a significant impact. The coronavirus pandemic had a significant influence on medicine development, production, and supply, as well as on the businesses of different healthcare corporations around the world. As cancer patients are more susceptible to viral infections, especially after chemotherapy, stem cell transplants, or surgery, the T-cell therapy market is particularly vulnerable to disruption from the coronavirus outbreak. COVID-19 has led CAR-T therapy medication clinical trials to be delayed. Production is also being suspended as a result of the international lockdown, which is producing supply chain concerns. However, now that COVID-19 vaccines are readily available, numerous authorities are trying to assure that life-saving medications and vaccines are supplied without interruption. As a result, the market is projected to stabilize in the future.
Recent Development
- In December 2021, Novartis had announced the launch of next-generation CAR-T platform named T-Charge which will serve as the foundation for various new investigational CAR-T cell therapies in the Novartis pipeline. T cell stemness, or the ability to self-renew and develop, is preserved by the T-Charge platform, resulting in a product with increased proliferative potential and fewer tired T cells. T-Charge allows CAR-T cells to expand predominantly inside a patient's body (in-vivo), removing the requirement for an extensive culture time outside of the body (ex-vivo).
Global Thymus (T)-Cell Therapy Market Scope
The thymus (T)-cell therapy market is segmented on the basis of modality, therapy, indication, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Modality
- Research
- Commercialized
Therapy
- CAR T-cell Based
- T Cell Receptor (TCR) Based
- Tumor Infiltrating Lymphocytes (TIL) Based
Indication
- Hematologic Malignancies
- Lymphoma
- Leukemia
- Myeloma
- Solid Tumors
- Melanoma
- Brain and Central Nervous System
- Liver Cancer
- Others
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Thymus (T)-Cell Therapy Market Regional Analysis/Insights
The thymus (T)-cell therapy market is analysed and market size insights and trends are provided by country, modality, therapy, indication, end-users and distribution channel as referenced above.
The countries covered in the thymus (T)-cell therapy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the thymus (T)-cell therapy market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players and rising healthcare expenditure will further propel the market’s growth rate in this region. Additionally, increasing research and development activities will further propel the market’s growth rate in this region.
Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to rising research and development in this region. Also, development of healthcare infrastructure and growing government initiatives will further propel the market’s growth rate in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Thymus (T)-Cell Therapy Market Share Analysis
The thymus (T)-cell therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to thymus (T)-cell therapy market.
Some of the major players operating in the thymus (T)-cell therapy market are:
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- Sanofi (France)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Bristol-Myers Squibb Company (US)
- Merck KGaA (Germany)
- Aurora Health Care (US)
- bluebird bio, Inc. (US)
- Amgen Inc. (US)
- Gilead Sciences, Inc. (US)
- Aurora Biopharma. (US)
- Fate Therapeutics (US)
- Mustang Bio (US)
- Sorrento Therapeutics Inc. (US)
- TCR² Therapeutics (US)
- Bayer AG (Germany)
- Bellicum Pharmaceuticals Inc. (US)
- AstraZeneca (UK)
- Johnson & Johnson Private Limited (US)
SKU-